ARTICLE

DNMT3A haploinsufficiency causes dichotomous DNA methylation defects at enhancers in mature human immune cells

Jung-Yeon Lim1, Sascha H. Duttke2, Turner S. Baker2, Jihye Lee3, Kristyne J. Gambino1, Nicholas J. Venturini1, Jessica Sook Yuin Ho1, Simin Zheng4, Yesai S. Fstkhchyan1, Vinodh Pillai4, David C. Fajgenbaum1, Ivan Marazzi3, Christopher Benner2, and Minji Byun1,6

DNMT3A encodes an enzyme that carries out de novo DNA methylation, which is essential for the acquisition of cellular identity and specialized functions during cellular differentiation. DNMT3A is the most frequently mutated gene in age-related clonal hematopoiesis. As such, mature immune cells harboring DNMT3A mutations can be readily detected in elderly persons. Most DNMT3A mutations associated with clonal hematopoiesis are heterozygous and predicted to cause loss of function, indicating that haploinsufficiency is the predominant pathogenic mechanism. Yet, the impact of DNMT3A haploinsufficiency on the function of mature immune cells is poorly understood. Here, we demonstrate that DNMT3A haploinsufficiency impairs the gain of DNA methylation at decommissioned enhancers, while simultaneously and unexpectedly impairing DNA demethylation of newly activated enhancers in mature human myeloid cells. The DNA methylation defects alter the activity of affected enhancers, leading to abnormal gene expression and impaired immune response. These findings provide insights into the mechanism of immune dysfunction associated with clonal hematopoiesis and acquired DNMT3A mutations.

Introduction

DNMT3A encodes a DNA methyltransferase that carries out DNA methylation, an evolutionarily conserved epigenetic mechanism critical for mammalian development (Smith and Meissner, 2013). The DNA methylation landscape in somatic cells is stably maintained at the genomic level except for tissue-specific regulatory regions (He et al., 2020). Perturbations of the deposition and removal of DNA methylation at these regions impair lineage fate decisions (Bröské et al., 2009; Trowbridge et al., 2009), indicating the importance of DNA methylation for the acquisition of proper cellular identity and specialized functions. DNMT3A is the most frequently mutated gene in clonal hematopoiesis (CH), which occurs when a clonal population of blood cells carrying advantageous somatic mutations expands faster than others. CH is strongly associated with aging, affecting >10% of individuals older than 65 yr (Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014). DNMT3A mutations, together with mutations in TET2, account for approximately two thirds of CH (Challen and Goodell, 2020). DNMT3A is also recurrently mutated in hematologic malignancies (Yang et al., 2015) and nonmalignant hematologic conditions, such as idiopathic multicentric Castleman disease (iMCD; Nagy et al., 2018). These observations prompted investigations into the role of DNMT3A in hematopoietic stem cells (HSCs), which found that complete Dnmt3a deficiency promotes self-renewal and clonal expansion of murine HSCs (Challen et al., 2011; Challen et al., 2014; Jeong et al., 2018). While the majority of studies on DNMT3A have focused on characterizing DNMT3A- or Dnmt3a-null cells, complete loss of DNMT3A is rare in humans. CH-associated DNMT3A mutations are typically heterozygous, and the majority of them are single-copy deletions, truncating mutations, or missense mutations affecting functionally critical protein domains (Challen and Goodell, 2020). These observations indicate that haploinsufficiency is the predominant pathogenic mechanism associated with DNMT3A mutations. DNMT3A-mutated CH carriers do not display gross abnormalities in the number or composition of circulating blood cell subsets (Dawoud et al., 2020). As such, mature immune cells carrying DNMT3A mutations can be

1Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY; 2Department of Medicine, University of California, San Diego, La Jolla, CA; 3Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY; 4Department of Pathology and Laboratory Medicine, The Children’s Hospital of Philadelphia, Philadelphia, PA; 5Department of Medicine, University of Pennsylvania, Philadelphia, PA; 6Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

Correspondence to Minji Byun: minji.byun@mssm.edu.

© 2021 Lim et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

https://doi.org/10.1084/jem.20202733
detected readily in individuals with CH (Arends et al., 2018; Buscarlet et al., 2018), raising a question about the impact of DNMT3A haploinsufficiency on these cells. Although DNMT3A haploinsufficiency has been studied in the context of hematopoietic malignancy (Cole et al., 2017; Haney et al., 2016) and neurodevelopmental impairments (Christian et al., 2020), its impact on mature immune cells has not been rigorously examined. Recent studies reported increased all-cause mortality and death due to atherosclerotic cardiovascular disease in CH carriers, including those with DNMT3A mutations (Jaiswal et al., 2014; Jaiswal et al., 2017). Corroborating this finding, CH with mutations in DNMT3A or TET2 is associated with poor outcomes in patients with heart failure (Dorsheimer et al., 2019). For TET2, these associations have been attributed to the proinflammatory nature of TET2-mutated myeloid cells based on murine studies (Fuster et al., 2017; Jaiswal et al., 2017; Sano et al., 2018a).

Although DNMT3A mutations are more common than TET2 mutations in CH, only limited characterization of DNMT3A-mutated myeloid cells has been reported to date (Leoni et al., 2021; Sano et al., 2018a). Importantly, the DNA methylation landscape of DNMT3A-haploinsufficient mature immune cells, which may provide mechanistic insights into the link between DNMT3A mutation-driven CH and the heightened risk of cardiovascular disease, remains poorly characterized. Given the central role that DNA methylation plays in the acquisition and reinforcement of cellular identity, we hypothesized that DNMT3A haploinsufficiency could cause functional impairments of mature immune cells through dysregulated DNA methylation. Here, we tested our hypothesis using genetically defined human macrophage models of DNMT3A haploinsufficiency.

**Results**

**Biochemical and functional characterization of DNMT3A haploinsufficiency in patient-derived cells**

We studied an adolescent patient diagnosed with iMCD (Hawkins and Pillai, 2015), a rare disorder characterized by biochemical and functional characterization of DNMT3A haploinsufficiency in patient-derived cells

Generation of human embryonic stem cell (hESC) models of DNMT3A haploinsufficiency

While iPSCs are valuable for basic assessment of DNMT3A haploinsufficiency in the native genetic background of patient-derived cells, they are not best suited for tracking cellular differentiation–associated changes in DNA methylation because cell-of-origin–specific DNA methylation patterns can remain in iPSCs (Kim et al., 2011). To interrogate the effect of DNMT3A haploinsufficiency in cells naive to prior differentiation, we generated DNMT3A-haploinsufficient hESCs by carrying out CRISPR-Cas9 gene editing. We chose the hESC line H1 (WA01, NIIhESC-10-0043) for our study because its epigenome has been comprehensively characterized (Bock et al., 2011; Moore et al., 2020; Kundaje et al., 2015). Guide RNAs targeting the PWPF domain were used to introduce frameshift mutations (Fig. 2 A). Three clones with distinct monoallelic frameshift mutations (DNMT3A<sup>Δ/−</sup>) were selected for downstream analyses (Fig. S2 A). Additionally, three clones with biallelic frameshift mutations (DNMT3A<sup>Δ/Δ</sup>) were selected to represent DNMT3A-null controls (Fig. S2 A). These clones that had undergone the same targeting and selection processes without acquiring
Mutations in the targeted loci were used as WT controls (DNMT3A+/−) throughout the study.

The DNMT3A+/− and DNMT3A−/− hESC clones expressed similar levels of pluripotency markers compared with the WT clones (Fig. S2 B), consistent with a previous report (Liao et al., 2015). DNMT3A mRNA levels were significantly lower in the DNMT3A+/− and DNMT3A−/− clones relative to the WT controls, presumably due to nonsense-mediated mRNA decay (Fig. 2 B). Immunoblotting confirmed decreased and undetectable levels of DNMT3A proteins in the DNMT3A+/− and DNMT3A−/− clones, respectively (Fig. 2 C). DNA methylation analysis with the EPIC array demonstrated a DNMT3A dosage-dependent decrease in the global mean of DNA methylation (Fig. 2 D). The majority of differentially methylated sites exhibited lower methylation in the DNMT3A+/− or DNMT3A−/− clones than in the WT controls (Fig. 2 E). Together, these results recapitulate the observations in the patient-derived iPSCs and validate genome-edited hESCs as a robust model for DNMT3A haploinsufficiency.

DNMT3A haploinsufficiency causes dichotomous DNA methylation defects in mature macrophages

To gain insights into the impact of DNMT3A haploinsufficiency in mature human immune cells, we employed hESC-derived macrophages as an experimental model. Macrophages were differentiated using an established embryoid body (EB)–based method with minor modifications (Buchrieser et al., 2017; van Wilgenburg et al., 2013). EBs were sequentially exposed to different cytokines that resemble hematopoietic specification and myeloid expansion, followed by directed terminal differentiation of nonadherent myeloid progenitors (MPs) to mature macrophages (Fig. 3 A). Expression of cell surface markers was examined in MPs and macrophages to confirm the mature phenotype of the latter (Fig. 3 B). Notably, the expression of DNMT3A is gradually increased over the course of differentiation, in contrast to the sharply diminished expression of DNMT3B (Fig. 3 C).

Using this method, we differentiated macrophages from WT, DNMT3A-haploinsufficient, and -null hESCs.
DNMT3A-haploinsufficient and -null macrophages did not display gross defects in cell surface marker expression or the ability to uptake zymosan and modified low-density lipoproteins (Fig. S3, A and B). Yet, the EPIC array analysis revealed a large number of differentially methylated sites in these cells (Fig. 3 D and Fig. S3 C). Compared to the predominantly hypomethylated phenotype of DNMT3A-mutated hESCs (Fig. 2 E), it was remarkable that one third to one half of differentially methylated sites were hypermethylated in DNMT3A-mutated macrophages (Fig. 3 D and Fig. S3 C). To determine whether these methylation defects were established before or after the terminal differentiation to macrophages, we tested the effect of knocking down DNMT3A in fully differentiated macrophages. WT macrophages transfected with a pool of DNMT3A-targeting siRNAs demonstrated a significant and sustained reduction in DNMT3A transcripts and proteins for at least 5 d compared with macrophages transfected with nontargeting control siRNAs (Fig. 3 E). However, none of the sites examined by the EPIC array were significantly differentially methylated between DNMT3A-targeting siRNA-treated and control siRNA-treated macrophages. Consistently, their mean methylation levels across all examined sites as well as the hypo- and hypermethylated sites in DNMT3A−/− hESC-derived macrophages were comparable (Fig. 3 F). These results refute the hypothesis that DNMT3A haploinsufficiency dynamically modulates DNA methylation in terminally differentiated macrophages and indicate that the methylation defects in DNMT3A-haploinsufficient macrophages are established during differentiation.

To determine at which differentiation stage the DNA methylation defects appear, we additionally profiled DNA methylation of WT and DNMT3A-haploinsufficient EBs and MPs. While the number of hypomethylated sites in DNMT3A-haploinsufficient cells increased gradually over the course of differentiation, the number of hypermethylated sites increased sharply between the MP and the macrophage stages (Fig. 3 G). Furthermore, hypomethylation affected sites that gain methylation during MP-to-macrophage transition (Fig. 3 H). Together, these results indicated that DNA methylation defects in DNMT3A-haploinsufficient macrophages were tightly linked to differentiation-associated DNA methylation gains and losses.
Figure 3. **DNMT3A** haploinsufficiency causes dichotomous DNA methylation defects in mature macrophages. (A) Schematic of the macrophage differentiation protocol. (B) WT H1 hESC-derived MP harvested at day 18 and macrophages harvested at day 32 were examined for expression of the indicated cell surface markers with flow cytometry. Gray histograms indicate isotype controls. Data are representative of two independent experiments. (C) Relative mRNA levels of **DNMT3A** and **DNMT3B** at the indicated differentiation stages were assessed by TaqMan gene expression assays. Eukaryotic 18S ribosomal RNA was used as an endogenous control. Each dot indicates a WT hESC clone and cells derived from it. Error bars represent the SEM. Data are representative of two independent experiments. (D) DNA methylation of macrophages differentiated from three WT, three **DNMT3A**+/−, and three **DNMT3A**−/− hESC clones were determined with the EPIC array. Proportions and numbers of hypo- or hypermethylated sites (left) and mean methylation (right) in **DNMT3A**-haploinsufficient macrophages compared with WT controls are shown. Each dot in the bar graph indicates a clone. Error bars represent the SEM. ns, P > 0.05; ***, P < 0.001 by Student’s t test. See Fig. S3 C for **DNMT3A**-null macrophage data. (E) **DNMT3A** levels in WT hESC-derived macrophages transfected with the indicated siRNAs.
Cell-type–specific enhancers are abnormally methylated in DNMT3A-haploinsufficient macrophages

Differentiation-associated DNA methylation gains and losses occur primarily at enhancers (Luo et al., 2018; Stadler et al., 2011). While the EPIC array provides comprehensive coverage of promoter regions, its coverage of enhancers is sparse (Pidsley et al., 2016). To obtain a single basepair resolution methylation map of all regulatory elements, including enhancers, we performed whole-genome bisulfite sequencing (WGBS) of WT, DNMT3A–haploinsufficient, and DNMT3A-null hESC-derived macrophages. More than 23 million CpG sites covered at least five times in each of all nine samples (three independent clones per genotype) were included in the differential methylation analysis, representing a 27-fold increase over the total number of methylation sites analyzed by the EPIC array.

The number of hypomethylated CpG sites and the degree of methylation loss were larger in DNMT3A-null macrophages than DNMT3A–haploinsufficient macrophages (Fig. 4 A). Highly methylated sites were the main target of hypomethylation in both DNMT3A–haploinsufficient and -null macrophages (Fig. 4 A). In comparison, while the number of hypermethylated sites and the degree of methylation gain were similar between DNMT3A–haploinsufficient and DNMT3A-null macrophages, lowly methylated sites were more frequently hypermethylated in DNMT3A-haploinsufficient macrophages than in DNMT3A-null macrophages (Fig. 4 A).

In agreement with the EPIC array data (Fig. 3 H), CpGs that gain methylation upon macrophase differentiation (macrophase–gain sites: methylation in macrophages > methylation in hESCs) were hypomethylated in DNMT3A-haploinsufficient and -null macrophages, whereas CpGs that lose methylation upon differentiation (macrophase–loss sites: methylation in macrophages < methylation in hESCs) were hypermethylated (Fig. 4 B). To dissect this phenotype further, we investigated whether the differentially methylated sites were associated with cell-type–specific chromatin states. Because uniformly processed macrophase chromatin states were not available, chromatin states of primary blood CD14+ monocytes were used as a proxy (Kundaje et al., 2015). The hypermethylated sites in DNMT3A-haploinsufficient macrophages were enriched with enhancer-like chromatin states (TssAPFlnk, Enh, TxFlnk, EnhG) of monocytes but not those of hESCs (Fig. 4, C and D; and Fig. S4, A and B). Consistently, the binding sites of transcription factors (TFs) active in macrophages, such as PU.1 and RUNX, were enriched near (≤100 bp) the hypermethylated sites (Fig. 4 E). In comparison, the hypomethylated sites were enriched with enhancer-like chromatin states of hESCs (Fig. 4, C and D; and Fig. S4, A and B) and were located in proximity to the binding sites of TFs active in ESCs and early hematopoietic progenitors, such as OCT4, TEAD, and GATA (Fig. 4 F).

DNMT3A defects cause DNA hypermethylation at cell-type–specific enhancers in primary myeloid cells and hESC-derived neurons

An overgrowth intellectual disability syndrome known as Tatton-Brown-Rahman syndrome (TBRS; Online Mendelian Inheritance in Man accession no. 615879) is caused by germline heterozygous mutations in DNMT3A (Tatton-Brown et al., 2014). The spectrum of TBRS-associated DNMT3A variants overlaps with that of CH-associated variants (Shen et al., 2017), encompassing missense variants affecting functional domains, truncating variants, and the dominant-negative Arg882 variants (p.Arg882His and p.Arg882Cys; Russler-Germain et al., 2014). We thus hypothesized that mature immune cells from a TBRS patient would display DNA methylation defects similar to what we observed in DNMT3A-mutated hESC-derived macrophages.

A previous study examined DNA methylation of monocytes and neutrophils from a 9-yr-old TBRS patient with a p.Arg882His mutation and his unaffected 13-yr-old sibling who is WT for DNMT3A (Spencer et al., 2017). The same study examined DNA methylation of CD34+ HSCs and progenitor cells, monocytes, and neutrophils isolated from healthy donors (Spencer et al., 2017). We used these publicly available WGBS datasets to identify CpGs that gain methylation during differentiation to monocytes (monocyte gain sites: methylation in monocytes > methylation in CD34+ cells) and those that lose methylation (monocyte loss sites: methylation in monocytes < methylation in CD34+ cells). As expected, monocyte-loss sites were enriched with monocyte enhancers and binding sites of TFs important for
Figure 4. Cell-type-specific enhancers are abnormally methylated in DNMT3A-haploinsufficient macrophages. (A) WGBS was performed for macrophages differentiated from three WT, three DNMT3A+/− and three DNMT3A−/− hESC clones. The number of significantly differentially methylated CpGs (left), the average difference in the methylation level (middle), and the distribution of WT macrophage methylation levels at hypo- and hypermethylated sites in DNMT3A+/− and DNMT3A−/− macrophages are shown. Error bars represent the SEM. (B) Methylation levels of WT, DNMT3A+/−, and DNMT3A−/− macrophages are compared at macrophage-gain sites and macrophage-loss sites. Mean Δ, mean differences in the methylation level. ****, P < 0.0001 by paired t test. (C) Two-sided Fisher’s exact test results (Log2 odds) for enrichment/depletion of monocyte chromatin states in hypo- and hypermethylated sites in DNMT3A+/− macrophage are shown (P < 0.05 for all tests). TssA, active TSS; TssAFlnk, flanking active TSS; Enh, enhancers. Actual values used for plotting are shown near each column. (D) Same as C for hESC chromatin states. (E) Top two significant TF binding motifs enriched near (±100 bp) the hypermethylated sites in DNMT3A+/− macrophage. (F) Top three significant TF binding motifs enriched near (±100 bp) the hypomethylated sites in DNMT3A+/− macrophage. (G) Schematic of a locus on chromosome 22 containing two genes, ADA2 (chr22:17,179,304–17,221,989) and CECR3 (chr22:17,256,859–17,266,733). DNA
monocyte differentiation (Fig. 5, A and B). Comparison of the TBRS patient’s monocytes and his sibling’s monocytes revealed a modest overall hypomethylation in the patient’s cells (Fig. 5 C, left), in agreement with the previous report (Spencer et al., 2017). A focused analysis of monocyte-gain sites also showed hypomethylation in the patient’s monocytes (Fig. 5 C, center). In contrast, at the monocyte-loss sites, the patient’s monocytes displayed significant hypermethylation compared with the sibling’s monocytes (Fig. 5 C, right). Similarly, the TBRS patient’s neutrophils displayed higher methylation levels than his sibling’s neutrophils at neutrophil-loss sites, which are enriched with neutrophil enhancers and binding sites of TFs important for neutrophil differentiation (Fig. 5, D–F). Together, these results provide evidence that DNMT3A mutations cause DNA hypermethylation at cell-type-specific enhancers in primary myeloid cells.

We wondered whether this phenomenon was specific to the hematopoietic lineage or could affect other cell lineages in a similar manner. A previous study of human motor neurons differentiated from WT and DNMT3A-null hESCs provided an opportunity to examine this issue (Ziller et al., 2018). Notably, this study used another hESC line, HUES64, and clones derived from it (Ziller et al., 2018). By analyzing publicly available WGBS data from this study (National Center for Biotechnology Information Gene Expression Omnibus [NCBI GEO] accession no. GSE90583), we identified CpGs that gain methylation (neuron-gain sites: methylation in motor neurons > methylation in hESCs) during hESC-to-motor neuron differentiation and those that lose methylation (neuron-loss sites: methylation in motor neurons < methylation in hESCs). We then compared the methylation levels of WT and DNMT3A-null hESC-derived motor neurons at these sites. DNMT3A-null motor neurons displayed significantly lower methylation at neuron-gain sites than WT controls (Fig. 5 G). In contrast, they displayed significantly higher methylation at neuron-loss sites (Fig. 5 G). Moreover, we observed enrichment of neuron TF binding sites near the hypermethylated sites and ESC TF binding sites near the hypomethylated sites (Fig. 5 H). These results indicate that DNMT3A defects cause similar DNA methylation defects across at least two independent cell lineages (hematopoietic and neuronal) and support an unexpected role for DNMT3A in promoting DNA demethylation at cell-type-specific enhancers during cellular differentiation.

DNA methylation defects alter enhancer activity
DNA methylation at CpG-rich promoters is associated with repression of gene expression (Deaton and Bird, 2011; Smith and Meissner, 2013). In comparison, the impact of DNA methylation on the activity of enhancers, which typically have low CpG density, is less well understood. We thus investigated whether the DNA methylation defects at enhancers in DNMT3A-haploinsufficient macrophages were associated with altered enhancer activity. The presence of enhancer RNAs (eRNAs) is a specific indicator of enhancer activity, outperforming predictions based on histone modification (Anderson et al., 2014; Tippens et al., 2020). Hence enhancer activity can be assessed by quantifying eRNAs using a method such as capped small RNA sequencing (csRNA-seq; Duttke et al., 2019). The csRNA-seq is based on the observation that RNA polymerase II initially creates a 20–60-nucleotide RNA with an m7G-5’ cap structure before stalling during transcription initiation (Gu et al., 2012; Nechaev et al., 2010). By isolating short RNAs from total RNA using size selection and enriching for 5’-capped RNAs, all transcription start sites (TSSs), including those from eRNAs and other rapidly processed or degraded transcripts, can be mapped genome wide and quantified (Duttke et al., 2019).

Application of the csRNA-seq to hESC-derived macrophages identified TSS clusters predominantly corresponding to TssA (promoters), TssAFlnk (flanking promoters), or Enh (enhancer) chromatin states of monocytes (Fig. 6 A; Kundaje et al., 2015), confirming that the csRNA-seq could robustly detect transcription initiation events at regulatory chromatin regions. We grouped the csRNA-seq TSS clusters into four bins based on the degree and the direction of DNA methylation changes during hESC-to-macrophage differentiation (Fig. 6 B): two groups that lose DNA methylation during differentiation (bin1 and bin2), a group with minimal methylation changes (bin3), and another that gains methylation during differentiation (bin4). Chromatin state analyses indicated that bin1 and bin2 were enriched with enhancers, whereas bin3 was enriched with promoters (Fig. 6 C). Roughly one half of detectable TSS clusters were members of bin1 or bin2, and the vast majority of the other half were members of bin3. Less than 2% of total TSS clusters fell into bin4 (Fig. 6 D).

Consistent with the observation made with genome-wide CpGs (Fig. 4 B), TSS clusters containing CpG sites that lose methylation during differentiation (bin1 and bin2) were hypermethylated in DNMT3A-haploinsufficient macrophages, and those that gain methylation during differentiation (bin4) were hypomethylated (Fig. 6 E). Because TSS clusters belonging to bin1 or bin2 far outnumber those belonging to bin4 (Fig. 6 D), these data indicate that the majority of transcriptionally active enhancers are hypermethylated in DNMT3A-haploinsufficient macrophages compared with WT macrophages. This observation underscores the importance of considering cell-type-specific activity of regulatory elements in determining cell-type-specific downstream effects of DNA methylation defects.

We next investigated the relationship between DNA methylation and enhancer activity. There were more hypermethylated TSS clusters (based on the average methylation level of all CpGs within a TSS cluster) with reduced activity than those with enhanced activity (bin1; Fig. 6 F). Conversely, there were more hypomethylated TSS clusters with enhanced activity...
than those with reduced activity (Fig. 6 F). Since each csRNA-seq TSS cluster (∼150 bp) can contain several CpGs that are independently regulated, we additionally examined whether csRNA-seq TSS clusters containing at least one significantly hyper- or hypomethylated CpG displayed differential activity. Consistent with the results based on the average methylation, we observed an inverse relationship between CpG methylation and enhancer activity (Fig. 6 G).

Compared with DNMT3A-haploinsufficient macrophages, DNMT3A-null macrophages demonstrated milder hypermethylation of the bin1 and bin2 TSS clusters and more pronounced hypomethylation of the bin4 TSS clusters (Fig. 6 H).

Figure 5. DNMT3A defects cause DNA hypermethylation at cell-type-specific enhancers in primary myeloid cells and hESC-derived neurons. Results of analyzing publicly available datasets: A–F (Spencer et al., 2017) and G and H (Ziller et al., 2018). (A) Two-sided Fisher’s exact test results (Log2odds) for enrichment/depletion of the monocyte enhancer chromatin state in monocyte-gain and monocyte-loss sites (P < 0.05 for both tests). (B) Top two significant TF binding motifs enriched near (±100 bp) the monocyte-loss sites. (C) Methylation levels of monocytes from a TTRS patient and his sibling are compared at all examined CpGs, monocyte-gain, and monocyte-loss sites. The number of CpG sites included in each analysis and mean differences in the methylation level (Δ) are shown. ****, P < 0.0001 by paired t test. (D) Same as A for neutrophils. (E) Top two significant TF binding motifs enriched near (±100 bp) the neutrophil-loss sites. (F) Same as C for neutrophils. (G) Methylation levels of motor neurons differentiated from WT or DNMT3A−/− HUES64-hESCs are compared at neuron-gain and neuron-loss sites. The number of CpG sites included in each analysis and mean differences in the methylation level (Δ) are shown. ****, P < 0.0001 by paired t test. (H) Top three significant TF binding motifs enriched near (±100 bp) the hyper- or hypomethylated sites in DNMT3A−/− motor neurons.
Figure 6. DNA methylation defects alter enhancer activity. (A) Proportions of csRNA-seq TSS clusters in hESC-derived macrophage corresponding to indicated monocyte chromatin states. (B) DNA methylation levels of WT hESCs and WT hESC-derived macrophages were determined for each csRNA-seq TSS cluster (average of all CpGs within a given TSS cluster), and their differential is plotted as a density plot. (C) csRNA-seq TSS clusters grouped as in B were annotated based on monocyte chromatin states. (D) The number of csRNA-seq TSS clusters belonging to each bin is shown. (E) Differences in the methylation levels between DNMT3A-haploinsufficient macrophages and WT controls for each TSS-cluster bin. Positive y-axis values indicate hypermethylation in DNMT3A-haploinsufficient macrophages. (F) csRNA-seq TSS clusters differentially expressed (P < 0.05) in DNMT3A-haploinsufficient macrophages compared with WT macrophages are grouped based on their bin membership. The No CpG group represents TSS clusters devoid of CpGs. Positive y-axis values indicate increased expression/activity. (G) csRNA-seq fold changes of TSS clusters containing at least one CpG site significantly hyper- or hypomethylated in DNMT3A-haploinsufficient macrophages are plotted, regardless of their bin membership. (H) Same as E for DNMT3A-null macrophages. (I) Same as F for DNMT3A-null macrophages. BivFlnk, flanking bivalent TSS/Enh; EnhBiv, bivalent enhancer; EnhG, genic enhancers; Het, heterochromatin; Quies, quiescent; ReprPC, repressed polycomb; ReprPCWk, weak repressed polycomb; Rpts, ZNF genes and repeats; TssBiv, bivalent/poised TSS; TxFlnk, transcribed at gene 5′ and 3′; Tx, strong transcription; TxWk, weak transcription.
Considering that absolute methylation levels at TSSs are typically low, this result was consistent with the reduced representation of lowly methylated sites among hypermethylated sites in DNMT3A-null macrophages compared with DNMT3A-haploinsufficient macrophages (Fig. 4 A). Consistently, only a modest bias toward reduced activity was observed for the bin1 TSS clusters, whereas more exaggerated enhancement of activity was observed for the bin4 clusters (Fig. 6 I). Notably, these results provide an example in which a phenotype of DNMT3A-haploinsufficient cells cannot be readily deduced from that of DNMT3A-null cells, cautioning against the use of gene ablation models for the investigation of haploinsufficiency-driven pathologies.

**DNMT3A haploinsufficiency causes complex alterations in gene expression**

Based on the dichotomous DNA methylation defects at thousands of enhancers and the associated alterations in enhancer activity, we anticipated that DNMT3A haploinsufficiency would have a complex impact on gene expression. Transcriptomic analyses revealed only a modest correlation between differential enhancer activity and differential expression of genes nearest to the enhancer (Fig. S5 A). This is not surprising, as (1) enhancer action often occurs over a long genomic distance and, therefore, the nearest-gene approach is suboptimal for linking an enhancer with its target genes (Marsman and Horsfield, 2012), and (2) factors other than transcription initiation events (measured by csRNA-seq), such as transcript degradation rates, also contribute to the steady-state transcript level (measured by RNA-seq). Nevertheless, we identified several loci, including the TLR5 locus in chromosome 1, that exhibit a correlation among enhancer DNA hypermethylation, decreased enhancer activity, and reduced gene expression (Fig. S5 B).

The elevated risk of atherosclerotic cardiovascular disease in DNMT3A-mutated CH carriers (Jaiswal et al., 2017) prompted us to examine whether DNMT3A haploinsufficiency alters the expression of inflammatory response genes. Dozens of genes involved in myeloid leukocyte activation (Fig. S5 C) were among the hundreds of genes differentially expressed between DNMT3A-haploinsufficient macrophages and WT controls at steady state (Fig. 7 A). Expression levels of several genes encoding chemokines, such as CXCL family members and S100A8/A9 heterodimer, were elevated in DNMT3A-haploinsufficient macrophages compared with WT controls (Fig. 7 A). Simultaneously, expression levels of genes encoding essential immune signaling molecules, such as TLR family members, phosphatidylinositol 3-kinases, tyrosine kinases, and ADA2, whose loss-of-function mutations are associated with a systemic autoinflammatory syndrome (Navon Elkan et al., 2014; Zhou et al., 2014), were reduced in DNMT3A-haploinsufficient macrophages (Fig. 7 A).

To test whether altered expression of these genes could affect an immune response, we focused on TLR4, one of the TLR genes underexpressed in DNMT3A-haploinsufficient macrophages (Fig. 7 A). TLR4 is critical for the recognition of LPS, which induces a robust inflammatory response in macrophages (Medzhitov, 2001). Accordingly, thousands of genes were induced or repressed in WT macrophages upon LPS stimulation (Fig. 7 B). In comparison, the strength of overall LPS response was diminished in DNMT3A-haploinsufficient macrophages as evidenced by reduced numbers of genes significantly induced or repressed by LPS (Fig. 7 B and Fig. S5 D). While expression levels of some LPS-induced cytokine genes, such as IL12B and IL1B, were lower in DNMT3A-haploinsufficient macrophages compared with controls, expression levels of others, such as TNF and IL6, were not significantly different or even higher in DNMT3A-haploinsufficient macrophages (Fig. 7, C–F). Together, these data demonstrate that DNMT3A haploinsufficiency is associated with complex alterations in gene expression, and it can cause immune dysfunction in a context-specific manner.

**Discussion**

DNA methylation defects involving both hypo- and hypermethylation have been observed in cells with complete deficiency of human DNMT3A or its murine orthologue Dnmt3a (Challen et al., 2011; Jeong et al., 2018; Jeong et al., 2014; Liao et al., 2015; Yagi et al., 2020; Ziller et al., 2018) as well as in Dnmt3a-haploinsufficient murine bone marrow cells, blood cells from a T-BRS patient, and B lymphoblastoid cell lines from a germline mosaic DNMT3A R771Q mutation carrier (Cole et al., 2017; Spencer et al., 2017; Tovy et al., 2020). These studies mainly focused on characterizing the scope and consequence of DNA hypomethylation. Comparatively, the DNA hypermethylation phenotype received little attention, in part because DNMT3A has been best characterized as a DNA methyltransferase, and, therefore, hypermethylation in DNMT3A-deficient cells is unexpected. While it has been speculated that hypermethylation may be caused by a compensatory mechanism in the complete absence of DNMT3A/Dnmt3a or a consequence of malignant transformation, our data demonstrate that DNA hypermethylation can occur in DNMT3A-haploinsufficient cells in the absence of malignant transformation.

Based on previous works as well as data reported in this study, we propose that DNMT3A plays a dual role in remodeling DNA methylation at enhancers during cell differentiation by (1) performing de novo DNA methylation of decommissioned stem cell/progenitor enhancers and (2) facilitating DNA demethylation of newly activated mature cell enhancers. DNMT3A haploinsufficiency impairs both these processes, resulting in hypomethylation of stem cell/progenitor enhancers and hypermethylation of mature cell enhancers. These DNA methylation defects suppress (hypermethylation) or enhance (hypomethylation) the activity of enhancers, ultimately driving complexly altered gene expression and functional impairment of the affected mature immune cells.

Notably, our data identify a previously unrecognized role of DNMT3A in facilitating active DNA demethylation. Emerging evidence nominates TET2 as the key enzyme that carries out DNA demethylation of enhancers (Hon et al., 2014; Rasmussen et al., 2019; Sardina et al., 2018). While DNMT3 and TET family members have been shown to compete at somatic enhancers in pluripotent cells (Charlton et al., 2020), they may have a cooperative interaction during cellular differentiation. It has been shown that DNMT3A is recruited to active enhancers in human…
epidermal stem cells, and DNMT3A knockdown results in a specific reduction in 5-hydroxymethylcytosine levels at active enhancers (Rinaldi et al., 2016). As 5-hydroxymethylcytosine is an essential intermediate of TET2-mediated DNA demethylation (Wu and Zhang, 2017), these data suggest that DNMT3A may assist in TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine and, ultimately, demethylation. Supporting this scenario, knockdown of TET2 increases DNA methylation uniquely at the DNMT3A-bound enhancers in human epidermal stem cells (Rinaldi et al., 2016). While future studies are needed to determine the precise interplay between DNMT3A and TET2 in enhancer DNA demethylation, it is noteworthy that DNMT3A and TET2 are frequently mutated in CH in a not mutually exclusive manner (Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014). Similar to DNMT3A, TET2 mutations associated with CH are loss-of-function mutations, raising the question of how loss-of-function mutations in genes encoding proteins with seemingly antagonistic enzymatic activity lead to similar clinical outcomes. The dependency of TET2-mediated DNA demethylation on DNMT3A can provide an answer to this puzzling question. Understanding whether and how DNMT3A haploinsufficiency impacts function of the affected immune cells has high public health significance because of (1) the high prevalence of DNMT3A mutations in age-related CH and the world’s rapidly aging population and (2) the association of CH with increased mortality and atherosclerotic cardiovascular disease (Jaiswal et al., 2014; Jaiswal et al., 2017). While prior studies reported that
acquired mutations in mechanism of immune dysregulation associated with aging and immune cells from CH carriers will further elucidate the discovery of DNA hypermethylation at cell-type specific enhancers in primary myeloid cells from a TBRS patient is one such discovery of DNA hypermethylation at cell-type-specific enhancers in primary myeloid cells. This complexity, which is consistent with the essential role of DNMT3A for remodeling DNA methylation of the Sendai virus in the iPSC clones was confirmed by performing semiquantitative PCR specific to Sendai virus as described in the manufacturer’s manual (Life Technologies). Expression of PSC markers was analyzed with LSRFortessa (BD Biosciences). Antibodies used were SSEA4, OCT3/4, NANOG, and SOX2 (Invitrogen). All antibodies were used as recommended by the manufacturer.

Generation of patient-specific iPSCs
Human iPSCs were generated from the patient’s PBMCs using integration-free Sendai virus vectors (CytoTune-IPS 2.0 Sendai Reprogramming Kits; Thermo Fisher Scientific) in collaboration with the Mount Sinai Pluripotent Stem Cell Core. iPSCs were cultured with StemFlex media (Gibco) on Cultrex (Amso) in feeder-free condition. Cells were passaged with Accutase (STEMCELL Technologies) and plated in StemFlex media containing 1 μmol/liter thiazovivin (Selleck Chemicals). Clearance of the Sendai virus in the iPSC clones was confirmed by performing semiquantitative PCR specific to Sendai virus as described in the manufacturer’s manual (Life Technologies). Expression of PSC markers was analyzed with LSRFortessa (BD Biosciences). Antibodies used were SSEA4, OCT3/4, NANOG, and SOX2 (Invitrogen). All antibodies were used as recommended by the manufacturer.

Generation of genome-edited hESC clones
hESC line H1 (WA01) was obtained from WiCell and maintained in feeder-free condition as described for iPSCs. H1 cells were transfected with plasmids containing Streptococcus pyogenes Cas9, EGFP, and a guide RNA (a gift of Eirini Papapetrou, Icahn School of Medicine at Mount Sinai, New York, NY) using the Neon Transfection System (Thermo Fisher Scientific). The following guide RNAs were used to target the PWWP domain of DNMT3A: 5'-GCTACACGCGTTAGGCAG-3' and 5'-TGGGCTAGTTCTCAGAGA-3'. After 48 h, EGFP+ cells were sorted with FACSaria and plated on irradiated mouse embryonic fibroblast feeder layer. Colonies were genotyped by amplifying genomic segments flanking the target sites and carrying out Sanger sequencing. Clones with mono- or biallelic frameshift mutations underwent an additional round of single-cell cloning to ensure clonality.

Quantitative RT-PCR measurements of DNMT3A and DNMT3B transcripts
Total RNA was extracted using Quick-RNA Kit (Zymo Research). Total RNA (500 ng) was reverse transcribed at 25°C for 10 min at 37°C for 2 h followed by 85°C for 5 min (Applied Biosystems). Multiplex quantitative PCR was performed using the following TaqMan gene expression assays: DNMT3A (Hs00173377), DNMT3B (Hs00171876), GAPDH (4326317E), and 18S rRNA (Hs99999901_s1), all from Thermo Fisher Scientific. Relative

Materials and methods
Whole-genome sequencing and analysis
Whole-genome sequencing and analysis was performed as previously described (Baker et al., 2018). Briefly, genomic DNA was extracted from granulocytes isolated with Ficoll density gradient centrifugation of whole blood from the iMCD patient and his parents using PAXgene Blood DNA Kit (QIAGEN). Samples were sequenced to 30× average coverage with 150-bp paired-end reads using an Illumina HiSeq X instrument. Raw sequence data were aligned to the human genome build GRCh38 with BWA-MEM, duplicates were marked with Picard, and base quality recalibration was performed with GATK. Single nucleotide variants and small insertions and deletions were jointly called with GATK HaplotypeCaller. Variants were annotated with Variant Effect Predictor (McLaren et al., 2016) followed by the creation of a GEMINI database (Palla et al., 2013).

Digital droplet PCR
T cell, B cell, and monocyte subsets were sorted from the patient’s PBMCs based on the cell surface expression of CD3, CD19, and CD14, respectively, using a FACSArria II sorter (BD Biosciences). Genomic DNA was extracted from each sorted cell populations using Zymo Quick-DNA Kit. Genomic DNA extracted from the pellet fraction of the Ficoll gradient was used to estimate variant allele frequency in granulocytes. Genomic DNA was isolated from formalin-fixed paraffin-embedded bone marrow and lymph node tissue slides using Zymo Quick-DNA FFPE Miniprep Kit. The following primers and probes were used for allele-specific digital droplet PCR: universal forward primer: 5’-ACTGTTGTAATGATTCTCTGCT-3’; universal reverse primer: 5’-GCCACCGAGAAGG-3’; WT DNMT3A-specific probe: 5’/5HEX/AGTTTCCCCACACCCA/3IABkFQ/-3’ and mutant-specific probe: 5’/-56-FAM/AGTTTCCCCACACCCA/3IABkFQ/-3’ (the reference and the mutated nucleotides are in bold). Primers and probes were custom synthesized (Integrated DNA Technologies). Digital droplet PCR was performed with reagents, supplies, and the QX200 instrument from Bio-Rad, following the manufacturer’s instruction.

Journal of Experimental Medicine
https://doi.org/10.1084/jem.20202733

Tet2-deficient murine macrophages are hyperinflammatory (Fuster et al., 2017; Jaiswal et al., 2017; Sano et al., 2018a; Sano et al., 2018b), a study of germline TET2 mutation carriers did not find evidence of enhanced proinflammatory cytokine and chemokine production by TET2-haploinsufficient human macrophages (Kaasinen et al., 2019). Our data suggest that DNMT3A haploinsufficiency alters gene expression in a complex manner, involving both over- and underexpression of many inflammatory response genes. This complexity, which is consistent with the essential role of DNMT3A for remodeling DNA methylation at thousands of enhancers during cellular differentiation, cautions against drawing conclusions based on results obtained under limited experimental conditions. Further investigations are needed to determine whether CH-associated TET2 and DNMT3A mutations promote a hyperinflammatory state of primary human myeloid cells.

While hESC-derived macrophages provide a robust genetically defined model system for molecular mechanistic studies, significant differences in cell ontology and gene expression profiles exist between these cells and primary human myeloid cells. This is an important limitation of our study. Nevertheless, the findings reported here can serve as the foundation for the epigenetic, transcriptomic, and functional investigation of primary mature immune cells with DNMT3A mutations. The discovery of DNA hypermethylation at cell-type-specific enhancers in primary myeloid cells from a TBRS patient is one such example. We anticipate that follow-up studies of primary mature immune cells from CH carriers will further elucidate the mechanism of immune dysregulation associated with aging and acquired mutations in DNMT3A as well as other CH-driver genes.

Lim et al.
DNMT3A haploinsufficiency in mature immune cells

Journal of Experimental Medicine
https://doi.org/10.1084/jem.20202733
mRNA expression levels of DNMT3A and DNMT3B were obtained using the 2−ΔΔCt method, using GAPDH or 18S rRNA levels for normalization.

**DNMT3A immunoblotting**

One million iPSCs or ESCs were lysed in 2× Laemmli sample buffer (Alfa Aesar) with β-mercaptoethanol and boiled at 95°C for 10 min. After removal of the insoluble fraction by centrifugation at 10,000 × g for 10 min, protein samples were separated by SDS gel electrophoresis and transferred to a polyvinylidene difluoride membrane (Immobilon-P). Membranes were stained with DNMT3A antibody (Cell Signaling Technology; 3598S) at a dilution of 1:1,000 or hrNRPM3/4 antibody (Bethyl Laboratories; A303-910A-T) at a dilution of 1:5,000 at 4°C overnight. After washing with Tris-buffered saline and Tween 20, HRP-conjugated anti-rabbit IgG (Cell Signaling Technology; 7074S) were added at a dilution of 1:10,000 and incubated for 1 h at room temperature. After washing, bands were detected using an enhanced chemiluminescence detection kit (Millipore) and Hyperfilm-ECL reagents (Amersham).

**Differentiation of hESCs to macrophages**

hESCs were washed with PBS and harvested by incubating the cells for 5 min at 37°C with Accutase. Cells were counted, washed with PBS, and resuspended at a final concentration of 1.25 × 10⁵ cells/ml in EB media containing mTeSR1 (STEMCELL Technologies), 50 ng/ml BMP-4 (R&D Systems), 20 ng/ml stem cell factor (R&D Systems), and 50 ng/ml vascular endothelial growth factor (R&D Systems). 100 μl of cell suspension in EB media supplemented with 10 μmol/liter thiazovivin (Selleck Chemicals) were added per well of a 96-well ultra-low adherence plate (Costar 7007), centrifuged at 100 × g for 3 min, and incubated for 8 d. EBs were fed at days 1 and 2 by aspirating 50 μl of used media and adding 50 μl of fresh EB media. At day 4, 100 μl of fresh EB media was added. EBs were fed at day 6 by aspirating 100 μl of used media and adding 100 μl of fresh EB media. At day 8, EBs were transferred into a 100-mm tissue culture plate (96 EBs per plate; USA Scientific) and resuspended in monocyte/macrophage differentiation media I consisting of X-VIVO 15 (Lonza) supplemented with 100 ng/ml M-CSF (R&D Systems), 25 ng/ml IL-3 (R&D Systems), 2 mM glutamax (Gibco), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco), and 55 μM β-mercaptoethanol (VWR International). Two thirds of the media was changed every 5 d. Nonadherent monocytes/macrophages were harvested from the supernatant every 5 d from day 10 to day 25 and cultivated on a new tissue culture plate for 7–10 d in differentiation media II consisting of X-VIVO 15 supplemented with 50 ng/ml M-CSF, 2 mM glutamax, 100 U/ml penicillin and 100 mg/ml streptomycin, and 55 μM β-mercaptoethanol for further maturation.

**Macrophage characterization**

hESC-derived macrophages were harvested using a cell scraper and resuspended in PBS for analysis. Expression of macrophage markers was evaluated with flow cytometry using LSRFortessa (BD Biosciences). Antibodies used were CD45, CD11b, CD14, and CD16 (eBioscience) and CD34 and CD43 (BioLegend). All antibodies were used as recommended by the manufacturer. For zymosan phagocytosis assay, hESC-derived macrophages were plated on tissue culture plates in RPMI 1640 (Gibco) with 10% heat-inactivated human serum (Sigma), 2 mM glutamax (Gibco), and 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco) for 1 d. On the day of the analysis, negative control cells were pre-treated with 10 μM cytochalasin D for 1 h. After pretreatment, all wells were fed with media containing two particles per cell of Alexa Fluor 488-labeled zymosan (Thermo Fisher Scientific) and incubated for 30 min at 37°C. Macrophages were detached using a cell scraper in PBS, and membrane-bound zymosan was quenched in 250 mg/ml trypsin blue (Gibco) for 5 min. Stained macrophages were analyzed with LSRFortessa (BD Biosciences). The modified low-density lipoprotein uptake assay, macrophages were incubated for 4 h with Dil-labeled acetylated low-density lipoprotein (Dil-AcLDL 5 μg/ml; Invitrogen) in RPMI 1640 containing 2 mM glutamax (Gibco) and 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco) at 37°C. Dil-AcLDL uptake was analyzed by flow cytometry with LSRFortessa (BD Biosciences). Dil-AcLDL uptake is represented as a percentage, with the untreated control indicated as 100%.

**DNMT3A silencing with siRNAs**

A pool of nontargeting siRNAs and a pool of DNMT3A-targeting siRNAs were purchased from Dharmacon. WT hESC-derived macrophages were plated in 24-well plates at 1.2 × 10⁵ cells per well for 24 h before transfection. Lipid–siRNA complexes were prepared by incubating 10 nM of siRNA with lipofectamine RNAiMAX (Life Technologies) in the volume recommended by the manufacturer. Lipid–siRNA complexes were added to the wells in a final volume of 500 μl of serum-free RPMI 1640. After incubation for 24 h, cells were washed and reincubated in RPMI 1640 containing 10% heat-inactivated human serum (Sigma). Total RNA was extracted 4 d after (5 d after the addition of siRNAs) for quantitative RT-PCR. Genomic DNA was extracted at the same time for the DNA methylation analysis with the EPIC array.

**DNA methylation array and analysis**

Genomic DNA was extracted from iPSCs, hESCs, hESC-derived EBs, MPs, and macrophages using Quick-DNA Kit (Zymo Research). DNA methylation levels were assessed with Infinium MethylationEPIC BeadChips (Illumina). We followed a Bioconductor workflow using multiple R packages for analyzing the methylation array data (Maksimovic et al., 2016). Briefly, the raw data were imported with minfi and normalized with the preprocessingQuantile method (Aryee et al., 2014). Cross-reactive probes (Chen et al., 2013) as well as probes that have failed in one or more samples were filtered out. A linear regression modeling using the limma package was used to identify the differentially methylated probes (Ritchie et al., 2015). CpG sites with Benjamini-Hochberg-adjusted P < 0.05 were considered significantly differentially methylated between groups.

**WGBS and analysis**

Genomic DNA was isolated from hESC-derived macrophages using Quick-DNA Kit (Zymo Research). Bisulfite conversion,
library preparation, and sequencing of the libraries were performed by Geneviz. Briefly, 100–200 ng of genomic DNA was fragmented using a Covaris S2. The sheared DNA was purified using the DNA Clean & Concentrator Kit (Zymo Research) per the manufacturer’s recommendations. Bisulfite conversion of DNA was conducted using the EZ DNA Methylation-Gold Kit (Zymo Research). Bisulfite-converted DNA was immediately processed for generating WGBS libraries using the Accel-NGS Methyl-Seq DNA Library Kit (Swift Biosciences), following the manufacturer’s protocol. The libraries were sequenced on an Illumina HiSeq 2500 sequencer as 150-bp paired-end reads. Quality- and adaptor-trimmed raw sequences were aligned to GRCh38/hg38 primary genome and deduplicated using Bismark (Krueger and Andrews, 2011). CpG methylation data extracted using the bismark_methylation_extractor was modified to construct a bseq object (Hansen et al., 2012), which was used for statistical testing with the DSS package (Feng et al., 2014) DMLtest with smoothing. Only CpG sites covered at least five times in all nine samples (three clones per group; \( n = 23,450,022 \)) were included in the DMLtest analysis. CallDML function with p.threshold = 0.05 was used to identify differentially methylated sites.

To determine macrophage-gain and -loss sites, the ENCODE project WGS data for H1-hESC was used (ENCSR617FKV, processed methylation state at CpG). For the chromatin state analyses, hg38-lifted 15-coremamn ob files for H1 (E003) and primary monocytes (E029) downloaded from the Roadmap Epigenomics project portal were used. For the TF binding motif analyses, findMotifsGenome.pl function of HOMER (Heinz et al., 2010) was used with the -size 200 option.

For the analysis of the TBRS patient vs. his sibling’s WGS data (Spencer et al., 2017), bigwig files for coverage and methylation levels for the patient’s and the sibling’s monocytes, neutrophiles, and T cells were downloaded from https://wustl.app.box.com/s/6n2f1htz6sgoh4vus2e9poffxeyd0vqmk. Only CpGs covered at least five times in all six samples (\( n = 18,212,634 \)) were included in the analysis shown in Fig. 5. From the same URL, WGS-based bigwig files for coverage and methylation levels for CD34-positive progenitor cells (six samples), monocytes (two samples), and neutrophils (three samples) from healthy donors were downloaded to determine monocyte-gain/loss sites and neutrophil-gain/loss sites. Because the coverages of individual CD34-positive samples were generally low (less than 1 million CpGs covered at least five times), data were collapsed for each cell type (CD34, monocytes, neutrophils) using the collapseBSseq function of the bsseq package. Only CpGs covered at least 10 times in collapsed CD34 and collapsed monocytes (\( n = 18,245,172 \)) were used to determine monocyte-gain and -loss sites using the DSS package DMLtest analysis (smoothing=True). Likewise, only CpGs covered at least 10 times in collapsed CD34 and collapsed neutrophils (\( n = 28,958,116 \)) were used to determine neutrophil-gain and -loss sites using the DSS package DMLtest analysis (smoothing=True). For the analysis of WGBS data of DNMT3A-deficient hESC-derived motor neurons (Ziller et al., 2018), the following data were downloaded from NCBI GEO under accession no. GSE90553: WGBS_hESC_KO3A_D0 (two samples), WGBS_hESC_KO3A_D14 (three samples), and WGBS_hESC_WT_D14 (four samples). Only CpGs covered at least five times in all 11 samples (\( n = 6,905,467 \)) were included in the DSS package DMLtest analysis with smoothing.

csRNA-seq and analysis

csRNA-seq was performed as described in Duttke et al. (2019). Total RNA was extracted from unstimulated hESC-derived macrophages using Quick-RNA Kit (Zymo Research). Small RNAs of ∼20–60 nt were size selected from 0.4–1 µg of total RNA by denaturing gel electrophoresis. A 10% input sample was taken aside, and the remainder was enriched for 5’- capped RNAs with 3’-OH. Monophosphorylated RNAs were selectively degraded by Terminator 5’-Phosphate-Dependent Exonuclease (Lucigen). Subsequent 5’ dephosphorylation by CIP (New England Biolabs [NEB]) followed by decapping with RppH (NEB) augments Capping specific 5’ adapter ligation by T4 RNA ligase 1 (NEB). The 3’ adapter was ligated using truncated T4 RNA ligase 2 (NEB) without prior 3’ repair to select against degraded RNA fragments. Following cdNA synthesis, libraries were amplified for 14 cycles and sequenced on the Illumina NextSeq 500 instrument as 75-bp single-end reads. Sequencing reads were trimmed for 3’ adapter sequences (AGATCGGAAGAGCACACGTCT) using HOMER (“homerTools trim”) and aligned using STAR with default parameters. TSS clusters were defined using HOMER’s findcsRNATSS.pl tool that automates the discovery of strand-specific regions enriched with csRNA-seq reads found within 150 bp with a minimum read depth of 7 reads per 10^5 aligned reads and greater than twofold reads per bp than the surrounding 10 kb. This step eliminates loci with minimal numbers of supporting reads or regions with high levels of diffuse signal. Short RNA input libraries and total RNA-seq were used to filter out likely false-positive TSS clusters. TSS clusters with at least three samples with a count of five or more were included for the differential expression analysis by DESeq2. TSS clusters with \( P < 0.05 \) was considered as significantly differentially expressed. For the TF binding motif analyses, the findMotifsGenome.pl tool of HOMER was used with -size -150,50 option.

RNA-seq and analysis

Total RNA was extracted from PBS-stimulated or LPS-stimulated (100 ng/ml for 4 h) hESC-derived macrophages using Quick-RNA Kit (Zymo Research). RNA-seq libraries were generated using Illumina TruSeq RNA Library Preparation Kits. Pools were sequenced on the Illumina HiSeq 2500 sequencer as 150-bp paired-end reads. RNA-seq data were analyzed using Bioconductor packages Salmon (Patro et al., 2017), tximeta (Love et al., 2020), and DESeq2 (Love et al., 2014), following the recommended RNA-seq workflow (Love et al., 2015). Only genes with at least three samples with a count of ≥10 were included for the differential expression analysis by DESeq2. Two independent experiments were pooled with batch effect correction by adding batch in the design formula of DESeq2. Genes with Benjamini-Hochberg-adjusted \( P < 0.05 \) were considered as significantly differentially expressed. Shrunken log2-fold changes based on the apeglm method (Zhu et al., 2019) was used for some of the plots.
Genomic and transcriptomic data
The EPIC array, WGBS, csRNA-seq, and RNA-seq data are available through NCBI GEO under accession no. GSE168722. The whole-genome sequence of the iMCD patient and his parents are deposited in NCBI dbGaP under accession no. phs001706.v1.p1.

Study approval
This study was approved by the institutional review boards of the Icahn School of Medicine at Mount Sinai and Washington University School of Medicine in St. Louis. Written informed consent was received from the iMCD patient and his parents before inclusion in the study.

Online supplemental material
Fig. S1 supplements Fig. 1 and shows the expression levels of pluri potency markers in WT and mutant iPSC clones derived from the iMCD patient. Fig. S2 supplements Fig. 2 and shows CRISPR/Cas9-edited hESC clones’ DNMT3A genotype and their expression levels of pluri potency markers. Fig. S3 supplements Fig. 3 and shows phenotypic characterization of macrophages derived from WT or DNMT3A-mutated hESCs. Fig. S4 supplements Fig. 4 and shows enrichment/depletion of cell type-specific chromatin states for differentially methylate sites in DNMT3A-null macrophages. Fig. S5 supplements Fig. 7 and shows transcriptomic characterization of DNMT3A-haploinsufficient macrophages.

Acknowledgments
The authors thank Eirini Papapetrou for sharing plasmids and protocols for CRISPR/Cas9-based genome editing of hESCs and the Flow Cytometry Core and Pluripotent Stem Cell Engineering Core at Icahn School of Medicine at Mount Sinai for their contributions.

This work was funded by Icahn School of Medicine at Mount Sinai, Castleman Disease Collaborative Network, Chan Zuck erberg Initiative Single-Cell Analysis of Inflammation Program, and National Institutes of Health (NIH) R01HL153597 to M. Byun; NIH K99GM135515 to S.H. Duttke; NIH U01AI135972 and GM134366 to C. Benner; the Burroughs Wellcome Fund, Chan Zuck erberg Initiative Neurodegeneration Challenge Network, Irma T. Hirsch Trust Young Investigator fellowship, and NIH U01AI150748 and R01AI43840 to I. Marazzi.

Author contributions: J.-Y. Lim designed experiments, performed iPSC and hESC characterization, generated and char acterized hESC-derived macrophages, analyzed the data, and wrote the manuscript. S.H. Duttke performed csRNA-seq. T.S. Baker performed digital droplet PCR and designed the guide RNAs for CRISPR-Cas9 targeting. J. Lee, K.J. Gambino, and N.J. Venturini generated CRISPR-Cas9–targeted hESCs. J.S.Y. Ho, S. Zheng, and Y.S. Fstkchyan analyzed the data. V. Pillai and D.C. Fajgenbaum provided the iMCD patient’s biopsy specimen. I. Marazzi and C. Benner analyzed and interpreted the data. M. Byun conceptualized the study, provided supervision, designed experiments, analyzed and interpreted the data, and wrote the manuscript. All authors edited the manuscript.

Disclosures: D.C. Fajgenbaum reported grants from EUSA Pharma and non-financial support from Pfizer outside the submitted work; in addition, D.C. Fajgenbaum had a patent for "Methods of Treating Idiopathic Multicentric Castleman Disease with JAK1/2 inhibition" pending (no licensee) and a patent for "Treatment of Castleman Disease" pending (no licensee). No other disclosures were reported.

Submitted: 23 December 2020
Revised: 4 March 2021
Accepted: 2 April 2021

References


DNMT3A haploinsufficiency in mature immune cells


dutta, K. Datta, and R. Opavsky. 2016. Dnmt3a is a haploinsufficient


iwaki-egawa, S., T. Yamamoto, and Y. Watanabe. 2006. Human plasma ad-


jeong, M., H.J. Park, H. Celik, E.L. Ostrander, J.M. Reyes, A. Guzman, B. Ro-


kaasinen, E., O. Kulisim, R. Rajamaki, H. Ristolainen, M. Aavikko, J. Kon-

Kervestin, S., and A. Jacobson. 2012. NMD: a multifaceted response to pre-


maksimovic, J., B. Phipson, and A. Oshlack. 2016. A cross-package Bio-


**Supplemental material**

**Figure S1.** Expression levels of pluripotency markers in the iMCD patient-derived iPSCs. Expression levels of the indicated pluripotency markers in WT and mutant iPSC clones were determined with flow cytometry. Data for a representative clone for each genotype are shown.

**Figure S2.** *DNMT3A* genotypes and expression levels of pluripotency markers in genome-edited hESCs. (A) Genotypes of *DNMT3A*-haploinsufficient and -null hESCs generated by CRISPR-Cas9 genome editing. (B) Expression levels of the indicated pluripotency markers were assessed with flow cytometry. Data for a representative clone for each *DNMT3A* genotype are shown.
Figure S3. **Characterization of DNMT3A+/− and DNMT3A−/− hESC-derived macrophages.** (A) Expression levels of the indicated cell surface markers were assessed with flow cytometry in macrophages derived from hESC clones with indicated DNMT3A genotype. (B) The ability to uptake fluorescently labeled zymosan and acetylated low-density lipoprotein (AcLDL) was assessed in the same set of cells as in A with flow cytometry. (C) Proportions and numbers of hypo- or hypermethylated sites (left) as well as mean methylation levels (right) in DNMT3A-null hESC-derived macrophages in comparison with WT controls are shown. Error bars represent the SEM. *** P < 0.001 by Student’s t test.

Figure S4. **Association of cell-type–specific chromatin states with differentially methylated sites in DNMT3A-haploinsufficient macrophages.** (A) Two-sided Fisher’s exact test results (Log2odds) for enrichment/depletion of monocyte chromatin states are shown (P < 0.05 for all tests). BivFlnk, flanking bivalent TSS/Enh; EnhBiv, bivalent enhancer; EnhG, genic enhancers; Het, heterochromatin; Ques, quiescent; ReprPC, repressed polycomb; ReprPCWk, weak repressed polycomb; Rpts, ZNF genes and repeats; TssBiv, bivalent/poised TSS; TXFlnk, transcribed at gene 5’ and 3’; TX, strong transcription; T WXK, weak transcription. (B) Same as A for hESC chromatin states.
Figure S5. Transcriptomic characterization of DNMT3A-haploinsufficient macrophages. (A) Comparison of eRNA fold-changes (DNMT3A\(^{+/−}\) over WT macrophages) as measured with csRNA-seq and mRNA fold-changes (DNMT3A\(^{+/−}\) over WT macrophages) of nearest genes as measured with RNA-seq. (B) Schematic of a locus on chromosome 1 containing TLR5 (chr1:223,109,404–223,143,248). PU.1 chromatin immunoprecipitation sequencing data of blood monocyte-derived macrophages is from a published study (Heinz et al., 2018). RNA-seq and csRNA-seq data from hESC-derived macrophages with indicated DNMT3A genotype are shown in green and red, respectively. DNA methylation levels at putative TLR5 enhancers (gray box) in WT and DNMT3A\(^{+/−}\) macrophages as well as WT H1-hESCs are shown. (C) A heatmap of genes with Gene Ontology term "myeloid leukocyte activation" (GO:0002274), expressed differentially between WT and DNMT3A-haploinsufficient macrophages. Each column indicates macrophages differentiated from an independent hESC clone. (D) The LPS-treated vs. PBS-treated gene expression fold-change distributions in WT and DNMT3A-haploinsufficient macrophages are shown in a density plot. The vertical dotted line indicates genes with no detectable expression difference between LPS- and PBS-treated conditions.